Gilead Sciences (GILD) Other financing activities (2009 - 2026)

Gilead Sciences (GILD) has 18 years of Other financing activities data on file, last reported at -$179.0 million in Q1 2026.

• Quarterly Other financing activities fell 1.7% year-over-year to -$179.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$443.0 million (down 29.91% YoY) and the FY2025 annual result came in at -$440.0 million, down 56.58% from the prior year.
• Other financing activities slipped to -$179.0 million in Q1 2026, from -$63.0 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of -$14.0 million in Q2 2022 to a low of -$179.0 million in Q1 2026.
• A 5-year average of -$79.5 million and a median of -$64.0 million in 2025 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities tumbled 133.33% — and 2024, when it advanced 14.07%.
• Tracing GILD's Other financing activities over 5 years: stood at -$23.0 million in 2022, then slumped by 47.83% to -$34.0 million in 2023, then slumped by 38.24% to -$47.0 million in 2024, then sank by 34.04% to -$63.0 million in 2025, then tumbled by 184.13% to -$179.0 million in 2026.
• The last three Other financing activities figures came in at -$179.0 million (Q1 2026), -$63.0 million (Q4 2025), and -$137.0 million (Q3 2025), per Business Quant data.